SpePharm gets €16mm in private round
SpePharm Holdings BV (cancer and critical care therapeutics) raised €16mm ($23.6mm) through a private financing from TVM Capital, Signet Healthcare Partners, Paul Capital Healthcare, and members of the company's senior management team. SpePharm concurrently announced a €10mm revenue interest acquisition financing agreement signed with Paul Capital to fund the recent purchase of European rights to Dantrium for hyperthermia from Procter & Gamble.
- Specialty Pharmaceuticals
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com